Therapeutic Advances and AE Management in NF1-Associated Plexiform Neurofibromas | Supplements and Featured Publications
Dr Gershon on Ongoing Research Priorities for NF1-Associated Plexiform Neurofibromas
August 11, 2025
Video
Timothy R. Gershon, MD, PhD, discusses ongoing research priorities neurofibromatosis type 1–associated plexiform neurofibromas
FDA Approval of Mirdametinib Reduces Treatment Barriers for Adult Patients With NF1-Associated PNs
August 07, 2025
Article
Timothy Gershon, MD, PhD, discusses how the FDA approval of mirdametinib will affect the treatment paradigm for adult patients with NF1-associated PNs.
Mirdametinib Represents Long-Awaited Approved Treatment Option for Adult NF1-Associated PNs
July 17, 2025
Article
Justin T. Jordan, MD, MPH, FAAN, discusses the implications of the FDA approval of mirdametinib for adult NF1-associated plexiform neurofibromas.
Dr Jordan on Challenges With Drug Development in Adult NF1-Associated PN
July 15, 2025
Video
Justin T. Jordan, MD, MPH, FAAN, discusses treatment challenges and recent progress made with targeted therapies in adult NF1-associated PNs.
MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD
May 12, 2025
Podcast
Dr Moertel discusses the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib and selumetinib.
Dr McNall-Knapp on the Efficacy of MEK Inhibition in NF1-Associated PNs
April 24, 2025
Video
Rene Y. McNall-Knapp, MD, discusses the current treatment paradigm for pediatric and adult patients with NF1-associated PNs.
Mirdametinib Use in NF1-Associated PNs Balances Efficacy and QOL Considerations
April 24, 2025
Article
Rene Y. McNall-Knapp, MD, discusses the symptom management associated with mirdametinib and MEK inhibition in NF1-associated PNs.
Dr Moertel on the Importance of Managing MEK Inhibitor–Associated Toxicites in NF1-Associated PN
April 03, 2025
Video
Christopher L. Moertel, MD, discusses the management of MEK inhibitor–associated toxicities in NF1-associated plexiform neurofibromas.
Effective Toxicity Management is Key to Maximizing Benefit With MEK Inhibitors in NF1-Associated PN
March 27, 2025
Article
Christopher L. Moertel, MD, discusses advances and ongoing research in NF1-associated plexiform neurofibromas.